UPDATE: Valeant Pharmaceuticals to Acquire Precision Dermatology for $475M

Valeant Pharmaceuticals International (NYSE: VRX ) today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality